FY2025 Earnings Forecast for CVKD Issued By Zacks Research

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Zacks Research issued their FY2025 earnings per share estimates for Cadrenal Therapeutics in a note issued to investors on Wednesday, February 25th. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of ($6.35) for the year. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Zacks Research also issued estimates for Cadrenal Therapeutics’ Q4 2025 earnings at ($1.12) EPS, FY2026 earnings at ($3.00) EPS and FY2027 earnings at ($2.36) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $32.00.

Cadrenal Therapeutics Price Performance

Shares of NASDAQ:CVKD opened at $8.49 on Friday. The business has a fifty day moving average price of $7.04 and a 200-day moving average price of $10.46. The company has a market capitalization of $19.87 million, a PE ratio of -1.06 and a beta of 1.18. Cadrenal Therapeutics has a 1-year low of $4.91 and a 1-year high of $20.39.

Insider Buying and Selling at Cadrenal Therapeutics

In other Cadrenal Therapeutics news, CFO Matthew K. Szot sold 9,933 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $6.97, for a total transaction of $69,233.01. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 26.09% of the company’s stock.

Institutional Investors Weigh In On Cadrenal Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. DRW Securities LLC purchased a new position in shares of Cadrenal Therapeutics in the 4th quarter valued at approximately $171,000. Citadel Advisors LLC acquired a new stake in Cadrenal Therapeutics during the 3rd quarter worth about $274,000. JPMorgan Chase & Co. purchased a new stake in Cadrenal Therapeutics during the 3rd quarter valued at about $103,000. Finally, Geode Capital Management LLC increased its holdings in shares of Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after purchasing an additional 1,818 shares during the period. Institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.